Portfolio overview
Our vision is to push the boundaries of artificial intelligence to solve complex challenges and shape a better future. We’re passionate about creating intelligent solutions that drive meaningful change across industries and communities. Through innovation, collaboration, and a commitment to excellence, we aim to set new standards in AI development.
Primo Biotechnology harnesses advanced molecular imaging and radiopharmaceutical science to provide precise clinical information via targeted radiopharmaceuticals. Primo Biotechnology aims to form a patient-centric healthcare model and establish doctor-patient relationships founded on trust towards conveying hope and happiness to all patients.
Founded in 2020, AcadeMab Biomedical Inc.s a start-up company dedicated to the development of new antibody drugs in the medical field that require urgent breakthroughs.
Founded in 2014, AnnJi Pharmaceutical Co., Ltd. (AnnJi) is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy).
We are dedicated to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to improve the treatment of human neurological conditions.
Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. See our Pipeline of therapeutics under development below to learn more about our commitment to bring better, next-generation as well as new first-in-class immunotherapies to patients.
UBI Pharma was established on July 31, 2014 as a spin-off company from United Biomedical, Inc., Asia. UBI Pharma specializes in developing and manufacturing fusion protein drugs and formulations of small molecule pharmaceuticals.
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients' quality of life and provide cure through innovative research. We are committed to apply the highest ethical standards to our products, services and communications. Foresee's core competency includes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.
TaiRx, Inc., a pharmaceutical company, focuses on the development of novel therapeutics with unmet medical needs. We target cancer as our first priority. Our team has extensive experience and knowledge in new drug development. This allows us to expedite the drug development process of our identified drug candidates going from early development to regulatory IND/NDA approval.
ACT Genomics is a cancer molecular information service company teamed up with experts with multiple years’ experience in oncology, cancer genomics, and bioinformatics. The company’s technology provides the possibility to transform cancer genomic information into precision diagnosis and personalized treatments.
BioResource International (BRI) is a biotechnology company specializing in the research, development and manufacture of high-performance enzymes that help poultry and swine producers optimize animal nutrition
Blend is developing novel cancer therapeutics designed to overcome biological barriers for treating cancer.
BioFirst Corporation focuses on the research, development, manufacture, and marketing of pharmaceutical products in Taiwan. The company develops products focusing on the clinical application of biomedical materials. It is developing FibroTest, a non-invasive liver disease detection system; Clover A1c, a HbA1c timely detection system; and GlucoPet A1C, a pet blood glucose monitoring system. The company was founded in 2006 and is headquartered in Taipei, Taiwan.
Holy Stone Healthcare Co., Ltd., founded in January 2001, is a subsidiary of Holy Stone Enterprise. Holy Stone Healthcare is committed to developing potential medical and biotech products. We are an international biotech company with several subsidiaries around the world. Till now, several patented biotech products were successfully developed and launched into the international market through our European subsidiaries.
Based on the development work, NTI is developing a patent portfolio in order to protect the commercialization of this novel therapeutic technique.
Selecta Biosciences is a clinical-stage biotechnology company developing an entirely new class of targeted immunotherapies and vaccines that precisely regulate immune responses to prevent and treat disease.
SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutial company focusing on creating values of new drug by R&D and integration of technology resources.
Savior Lifetec Corporation (SLC) is a specialty injectable company based in Chunan, Taiwan. Their facilities comply with the highest quality standards, having passed inspections by authorities from the US, EU, and Japan. SLC also has dedicated state-of-the-art GLP compliant R&D centers for API research and pharmaceutical research.
JHL Biotech ("JHL") is a start-up company founded in 2012 with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation.
